Voyager Therapeutics, Inc. (VYGR)
1.61
0.00 (0.00%)
USD |
NASDAQ |
Nov 20, 09:39
Voyager Therapeutics Cash from Operations (Quarterly) : -19.67M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -19.67M |
| June 30, 2026 | -25.84M |
| March 31, 2026 | -33.42M |
| December 31, 2025 | -30.26M |
| September 30, 2025 | -31.05M |
| June 30, 2025 | -33.26M |
| March 31, 2025 | -37.90M |
| December 31, 2024 | -14.53M |
| September 30, 2024 | -27.97M |
| June 30, 2024 | -31.58M |
| March 31, 2024 | 58.77M |
| December 31, 2023 | -23.76M |
| September 30, 2023 | -21.05M |
| June 30, 2023 | -0.835M |
| March 31, 2023 | 123.56M |
| December 31, 2022 | -12.24M |
| September 30, 2022 | -16.20M |
| June 30, 2022 | -18.49M |
| March 31, 2022 | 34.43M |
| December 31, 2021 | 11.20M |
| September 30, 2021 | -20.71M |
| June 30, 2021 | -22.72M |
| March 31, 2021 | -21.29M |
| December 31, 2020 | -21.98M |
| Date | Value |
|---|---|
| September 30, 2020 | -24.74M |
| June 30, 2020 | -21.20M |
| March 31, 2020 | -28.80M |
| December 31, 2019 | -23.36M |
| September 30, 2019 | -21.58M |
| June 30, 2019 | -31.56M |
| March 31, 2019 | 125.16M |
| December 31, 2018 | -24.35M |
| September 30, 2018 | -17.65M |
| June 30, 2018 | -22.50M |
| March 31, 2018 | 48.61M |
| December 31, 2017 | -14.83M |
| September 30, 2017 | -15.89M |
| June 30, 2017 | -16.34M |
| March 31, 2017 | -14.29M |
| December 31, 2016 | -13.09M |
| September 30, 2016 | -10.19M |
| June 30, 2016 | -9.714M |
| March 31, 2016 | -9.487M |
| December 31, 2015 | -9.557M |
| September 30, 2015 | -6.75M |
| June 30, 2015 | -6.982M |
| March 31, 2015 | 64.59M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Lineage Cell Therapeutics, Inc. | -5.62M |
| Armata Pharmaceuticals, Inc. | -5.516M |
| Black Diamond Therapeutics, Inc. | -8.338M |
| Invivyd, Inc. | -32.11M |
| Elicio Therapeutics, Inc. | -10.36M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 29.27M |
| Cash from Financing (Quarterly) | 3.033M |
| Free Cash Flow | -109.83M |
| Free Cash Flow Per Share (Quarterly) | -0.3181 |
| Free Cash Flow to Equity (Quarterly) | -17.61M |
| Free Cash Flow to Firm (Quarterly) | -19.67M |
| Free Cash Flow Yield | -109.7% |